KRAS and lung cancer: Genetically, BM and primary lung tumor harbored somatic mutations majorly in TP53 (75.00% BM, 69.23% lung), EGFR (30.00% BM, 46.15% lung) and KRAS (25.00% BM, 15.38% lung), and BM diverged from primary lung cancer with more frequent alterations in MLL3, ATRX, and RB1 (Fig. 1B).